IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas

STAR-VACC is a randomized double-blind controlled Phase 2 study assessing clinical efficacy of IDH1-vac in patients with newly diagnosed IDH1-mutant high-grade astrocytomas. Over a period of three years, patients with astrocytoma, WHO grade 3-4, will receive up to 12 vaccinations with either IDH1-vac or IS-vac. Screening will be performed after completion of radiotherapy. In the primary treatment phase consisting of 8 vaccinations, patients will receive concurrently SOC temozolomide (up to 12 cycles). Vaccinations will start approx. 4 to 8 weeks after completion of SOC radiotherapy.